USD 5.28
(6.45%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | 15.01 Million USD | -29.56% |
2022 | 21.31 Million USD | 16.0% |
2021 | 18.37 Million USD | 4773.74% |
2020 | 377 Thousand USD | -99.07% |
2019 | 40.43 Million USD | 6.48% |
2018 | 37.97 Million USD | 146785.47% |
2017 | -25.88 Thousand USD | 97.51% |
2016 | -1.04 Million USD | -2225.28% |
2015 | 48.93 Thousand USD | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q2 | 20.51 Million USD | -14.54% |
2024 Q1 | 26.87 Million USD | 79.0% |
2023 Q4 | 15.01 Million USD | -43.96% |
2023 Q3 | 26.79 Million USD | -25.23% |
2023 FY | 15.01 Million USD | -29.56% |
2023 Q2 | 35.83 Million USD | 6.45% |
2023 Q1 | 33.66 Million USD | 57.93% |
2022 FY | 21.31 Million USD | 16.0% |
2022 Q4 | 21.31 Million USD | -9.16% |
2022 Q2 | 19.33 Million USD | -13.29% |
2022 Q3 | 23.46 Million USD | 21.36% |
2022 Q1 | 22.29 Million USD | 21.35% |
2021 Q4 | 18.37 Million USD | 86.56% |
2021 FY | 18.37 Million USD | 4773.74% |
2021 Q1 | 21.71 Million USD | 5659.68% |
2021 Q2 | 22.41 Million USD | 3.23% |
2021 Q3 | 9.84 Million USD | -56.06% |
2020 Q3 | 78.21 Million USD | 4.49% |
2020 FY | 377 Thousand USD | -99.07% |
2020 Q4 | 377 Thousand USD | -99.52% |
2020 Q2 | 74.85 Million USD | 18.62% |
2020 Q1 | 63.1 Million USD | 56.08% |
2019 FY | 40.43 Million USD | 6.48% |
2019 Q4 | 40.43 Million USD | -48.08% |
2019 Q3 | 77.87 Million USD | 10.93% |
2019 Q2 | 70.2 Million USD | 22.08% |
2019 Q1 | 57.5 Million USD | 51.44% |
2018 FY | 37.97 Million USD | 146785.47% |
2018 Q3 | 697.29 Thousand USD | 69.83% |
2018 Q4 | 37.97 Million USD | 5345.47% |
2018 Q2 | 410.58 Thousand USD | 104.78% |
2018 Q1 | 200.5 Thousand USD | 874.58% |
2017 Q1 | -486.2 Thousand USD | 53.25% |
2017 Q2 | -286.45 Thousand USD | 41.08% |
2017 Q3 | -117.72 Thousand USD | 58.9% |
2017 Q4 | -25.88 Thousand USD | 78.01% |
2017 FY | -25.88 Thousand USD | 97.51% |
2016 Q4 | -1.04 Million USD | 26.83% |
2016 FY | -1.04 Million USD | -2225.28% |
2016 Q2 | 68.93 Thousand USD | 0.0% |
2016 Q3 | -1.42 Million USD | -2161.87% |
2015 FY | 48.93 Thousand USD | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Esperion Therapeutics, Inc. | 458.69 Million USD | 96.727% |
Theratechnologies Inc. | 24.87 Million USD | 39.637% |
Safety Shot Inc | -2.28 Million USD | 757.204% |
Cosmos Health Inc. | 8.59 Million USD | -74.758% |
Cronos Group Inc. | -663.32 Million USD | 102.263% |
Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 97.592% |
Kala Pharmaceuticals, Inc. | -14.57 Million USD | 203.026% |
Universe Pharmaceuticals INC | 197.2 Thousand USD | -7512.736% |
ProPhase Labs, Inc. | 19.23 Million USD | 21.933% |
Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 695.754% |
Dynavax Technologies Corporation | 106.63 Million USD | 85.921% |
Radius Health, Inc. | 359.28 Million USD | 95.821% |
China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 259.209% |
Alvotech | 1.06 Billion USD | 98.589% |
Sunshine Biopharma, Inc. | -15.63 Million USD | 196.024% |
Alpha Teknova, Inc. | 1.97 Million USD | -660.537% |
Intra-Cellular Therapies, Inc. | -130.82 Million USD | 111.475% |
SCYNEXIS, Inc. | -19.35 Million USD | 177.587% |
Harrow Health, Inc. | 116.41 Million USD | 87.104% |
Biofrontera Inc. | 4.05 Million USD | -270.143% |
DURECT Corporation | -7.65 Million USD | 296.146% |
Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 144.779% |
ANI Pharmaceuticals, Inc. | 94.2 Million USD | 84.064% |
OptiNose, Inc. | 58.06 Million USD | 74.144% |
RedHill Biopharma Ltd. | -5.18 Million USD | 389.489% |
Aquestive Therapeutics, Inc. | 74.95 Million USD | 79.969% |
Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -13949.355% |
SIGA Technologies, Inc. | -148.68 Million USD | 110.097% |
Lifecore Biomedical, Inc. | 121.89 Million USD | 87.684% |
Shineco, Inc. | 29.29 Million USD | 48.744% |
Phibro Animal Health Corporation | 454.84 Million USD | 96.699% |
Procaps Group S.A. | 242.93 Million USD | 93.82% |
TherapeuticsMD, Inc. | 3.67 Million USD | -308.184% |
Regencell Bioscience Holdings Limited | -2.9 Million USD | 617.435% |
Viatris Inc. | 17.13 Billion USD | 99.912% |
Sunshine Biopharma, Inc. | -15.63 Million USD | 196.024% |
Rockwell Medical, Inc. | 4.45 Million USD | -236.917% |
Incannex Healthcare Limited | -5.48 Million USD | 373.71% |
Aytu BioPharma, Inc. | -4.87 Million USD | 407.833% |
Tilray Brands, Inc. | 158.97 Million USD | 90.556% |
Collegium Pharmaceutical, Inc. | 435.33 Million USD | 96.551% |
PetIQ, Inc. | 351.93 Million USD | 95.734% |
Silver Spike Investment Corp. | -32.61 Million USD | 146.036% |
Neurocrine Biosciences, Inc. | 177.3 Million USD | 91.532% |
Journey Medical Corporation | -9.7 Million USD | 254.63% |
Alimera Sciences, Inc. | 55.3 Million USD | 72.856% |
Petros Pharmaceuticals, Inc. | -5.06 Million USD | 396.677% |
Assertio Holdings, Inc. | -32.52 Million USD | 146.153% |
Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 1108.449% |
Embecta Corp. | 1.31 Billion USD | 98.856% |
Cyclo Therapeutics, Inc. | -8.21 Million USD | 282.785% |
Procaps Group, S.A. | 242.93 Million USD | 93.82% |
PainReform Ltd. | -7.95 Million USD | 288.843% |
Avadel Pharmaceuticals plc | 4.21 Million USD | -256.011% |
Hempacco Co., Inc. | 13.61 Million USD | -10.271% |
Talphera, Inc. | -5.72 Million USD | 362.419% |
Pacira BioSciences, Inc. | 432.74 Million USD | 96.531% |
Alvotech | 1.06 Billion USD | 98.589% |
Lantheus Holdings, Inc. | -96.71 Million USD | 115.524% |
Kamada Ltd. | -46.43 Million USD | 132.334% |
Indivior PLC | -33.95 Million USD | 144.218% |
Currenc Group, Inc. | -16.57 Million USD | 190.586% |
Evoke Pharma, Inc. | 260.57 Thousand USD | -5661.511% |
Flora Growth Corp. | -713 Thousand USD | 2205.61% |
Cyclo Therapeutics, Inc. | -8.21 Million USD | 282.785% |
Evolus, Inc. | 63.7 Million USD | 76.435% |
HUTCHMED (China) Limited | -197.45 Million USD | 107.603% |
Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 96.866% |
Akanda Corp. | 3.9 Million USD | -284.464% |